Furthermore, individuals with classical CF who are heterozygous for F508del and an MF CFTR mutation (approximately 30%) do not show any improvement with either dual CFTR-modulator combination of LUM/IVA or TEZ/IVA [75,85]. The gene discussed is CFTR; the disease is cystic fibrosis.